InSitu Biologics touted preclinical data for its non-opiate, hydrogel-based painkiller, AnestaGel, for use in peri-operative regional pain management. The St. Paul, Minn.-based company designs therapies using its Matrix biohydrogel material.
Independent tests compared operative site injections of AnestaGel and Pacira Pharmaceutical’s (NSDQ:PCRX) Exparel. According to InSitu, the data showed that AnestaGel lasted longer and provided a greater analgesic effect than Exparel. Another test showed that bupivacaine, the painkiller used in both AnestaGel and Exparel, was released from AnestaGel and stayed in the blood longer than Exparel and bupivacaine injections.
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.